The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic mutation. The goal of the TAPUR study will be to utilize Food and Drug Administration (FDA)-approved targeted therapies with the intention of finding additional uses for those already approved drugs. In other words, one of the primary aims of the trial is to find new cancers that can be effectively treated with medications that are already approved. This will be based on looking for genetic defects in the new cancers and seeing if an already approved (albeit for a different cancer) drug might help. The targeted therapies will be provided by collaborating pharmaceutical companies. The choice of molecular profiling test used by clinical oncologists will be catalogued and studied as well. Results from this trial will be utilized in order to develop hypotheses for additional clinical trials.
The available drugs to eligible patients on the trial include Erlotinib, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab, Pertuzumab, Vemurafenib, Cobimetinib, Pembrolizumab Vismodegib, Cetuximab, Dasatinib, Regorafenib, and Olaparib. The TAPUR study is designed for patients with a locally advanced or metastatic solid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma for whom:
- Standard treatment hasn’t worked,
- Standard treatment has stopped working, or
- There is no standard treatment for that type and stage of cancer.
Chronic Lymphocytic Leukemia (CLL) patients can be enrolled on the trial, as CLL is considered a type of B-Cell non-Hodgkin lymphoma.
TAPUR is a landmark study, as it represents the first clinical research study undertaken by the American Study of Clinical Oncology (ASCO). The principal investigator of the trial and chair of the ASCO TAPUR steering committee is Edward Kim, MD, Chair, Solid Tumor Oncology and Investigational Therapeutics at the Levine Cancer Institute in Charlotte, NC, where the trial is currently open for enrollment. There are currently a total four sites enrolling on this trial. For more information regarding eligibility for enrollment specific to CLL, contact Ryan Jacobs, MD, CLL specialist and head of CLL clinical trials at Levine Cancer institute firstname.lastname@example.org.
Ryan Jacobs, MD is a hematologist/oncologist specializing in chronic lymphocytic leukemia at the Levine Cancer Institute, which is part of the Carolinas Health Care System in Charlotte, NC. He is also a Clinical Assistant Professor of Medicine and the UNC-Chapel Hill School of Medicine in Chapel Hill, NC
Originally published in The CLL Tribune Q2 2016